Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponatinib - Takeda

Drug Profile

Ponatinib - Takeda

Alternative Names: AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; Iclusig; Ponatinib hydrochloride

Latest Information Update: 22 Dec 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Dana-Farber Cancer Institute; Fundacion CRIS de Investigacion para Vencer el Cancer; Incyte Corporation; Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Otsuka Beijing Research Institute; Otsuka Pharmaceutical; Takeda; University of Birmingham; University of Colorado at Denver
  • Class Antineoplastics; Benzamides; Imidazoles; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Acute myeloid leukaemia; Biliary cancer; Gastrointestinal stromal tumours; Lung cancer; Squamous cell cancer; Thyroid cancer
  • Phase I/II Haematological malignancies; Solid tumours

Most Recent Events

  • 19 Dec 2020 Launched for Chronic myeloid leukaemia (Second-line therapy or greater, In adults) in USA (PO)
  • 18 Dec 2020 Registered for Chronic myeloid leukaemia (Second-line therapy or greater, In adults) in USA (PO)
  • 18 Dec 2020 Updated efficacy and adverse events data from the phase II OPTIC trial in Chronic myeloid leukaemia released by Takeda
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top